Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

38480results about "Cardiovascular disorder" patented technology

Dosing of muscle targeting complexes for treating dystrophinopathies

Aspects of the disclosure relate to methods of promoting expression or activity of a dystrophin protein and / or methods of treating DMD in a subject. In some embodiments, the methods comprise administering to the subject a composition comprising complexes (e.g., muscle targeting complexes) comprising a phosphorodiamidate morpholino oligomer (e.g., useful for targeting DMD) covalently linked to an antibody (e.g., anti-TfR1 antibody).
Owner:DYNE THERAPEUTICS INC

Fused pyridines for the treatment of cancer and other indications

PCT designated stage expiredWO2025034858A1Organic active ingredientsOrganic chemistrySmall GTPaseBiochemistry
Provided herein are compounds of Formula I" and Formula II and compositions thereof that are capable of disrupting, interrupting, and / or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof.
Owner:THERAS INC +2

Fused pyridazines for the treatment of cancer and other indications

PCT designated stage expiredWO2025034849A1Organic active ingredientsOrganic chemistryPyridazineSmall GTPase
Provided herein are compounds of Formula (I) and Formula (II) and compositions thereof that capable of disrupting, interrupting, and / or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Kα). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof. (I) (II)
Owner:THERAS INC +2

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC

Thiazolo tetrahydrochinoline compounds as class ii phosphoinositide 3-kinase inhibitors

The invention relates to chemical compounds useful as inhibitors of class II phosphoinositide 3- kinase (PI3K) signalling. The invention further relates to the medical use of inhibitors of class II phosphoinositide 3-kinase (PI3K) signalling in the treatment of medical conditions associated with defective and / or pathologic class II phosphoinositide 3-kinase (PI3K) signaling, such as stroke, a cardiovascular disease related to endothelial cell dysfunction, cancer, cancer metastasis, myopathy and diabetes.
Owner:FORSCHUNGSVERBUND BERLIN EV

Systems and methods for processing electronic images to quantify coronary microvascualar disease

A computer-implemented method for processing electronic images to quantify coronary microvascular disease may include receiving imaging data of one or more captured electronic images. A first set of the imaging data may have been captured prior to an administration of one or more pharmacological agents, and a second set of the imaging data may have been captured subsequently. The method may further include providing the imaging data and a set of patient data to a machine-learning model. The machine-learning model may have been trained to identify coronary microvascular disease (CMD) features within the captured imaging data and the set of patient data and output one or more CMD measures and / or a predicted CMD endotype. The method may further include transmitting, to a user device, the one or more CMD measures and / or the predicted CMD endotype.
Owner:HEARTFLOW INC

Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof

The present invention relates to a nitrogen-containing heterocyclic derivative inhibitor, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as an inhibitor in the treatment of diseases such as cardiovascular diseases and cerebrovascular diseases, wherein the definition of each substituent in general formula (I) is the same as that defined in the description.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Cyclopentane derivative-containing inhibitor as well as preparation method and application thereof

The invention relates to an inhibitor containing cyclopentane derivatives as well as a preparation method and application of the inhibitor. Particularly, the invention relates to a compound shown in a general formula (I), a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as an inhibitor in treatment of cardiovascular diseases, cerebrovascular diseases and other diseases, and substituents in the general formula (I) are as defined in the specification. # imgabs0 #
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.
Owner:DYNE THERAPEUTICS INC

Intein proteins and uses thereof

PendingJP2025020111ASenses disorderSplicing alterationInteinProtein reconstitution
To provide constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5Kb.SOLUTION: The present invention implements cellular large protein reconstitution by providing to a target cell two or more fragments of large protein fused to split inteins to promote intein-mediated trans-splicing and reconstitute the functional protein.SELECTED DRAWING: None
Owner:FOND AZIONE TELETHON

Dry powder composition comprising long-chain RNA

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry 10 powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
Owner:CUREVAC SE

Compounds, compositions, and methods

PCT designated stage expiredWO2025015269A1Organic active ingredientsNervous disorderDiseaseCalcitonin receptor
The present application discloses compounds of formula I for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.
Owner:ACONCAGUA BIO INC

Systems and methods for processing electronic images to quantify coronary microvascualar disease

A computer-implemented method for processing electronic images to quantify coronary microvascular disease may include receiving imaging data of one or more captured electronic images. A first set of the imaging data may have been captured prior to an administration of one or more pharmacological agents, and a second set of the imaging data may have been captured subsequently. The method may further include providing the imaging data and a set of patient data to a machine-learning model. The machine-learning model may have been trained to identify coronary microvascular disease (CMD) features within the captured imaging data and the set of patient data and output one or more CMD measures and / or a predicted CMD endotype. The method may further include transmitting, to a user device, the one or more CMD measures and / or the predicted CMD endotype.
Owner:HEARTFLOW INC

Method for diagnosing and / or evaluating retinal disease

InactiveUS20120087864A1increases the effective pharmacokineticsincrease concentrationSenses disorderOrganic active ingredientsDiseaseRetinal function
The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).
Owner:R TECH UENO

Composition for treating il-6-related diseases

The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.
Owner:CHUGAI PHARMA CO LTD

Composition beneficial to improvement of brain cognition, memory and sleep and used for preventing and improving Alzheimer's disease

The invention provides a composition beneficial to improvement of brain cognition, memory and sleep and prevention and improvement of Alzheimer's disease, and belongs to the technical field of health food. The composition comprises L-alpha-glycerophosphorylcholine (GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea leaf theanine (L-theanine), vitamin B groups, vitamin D3 and the like, and is prepared into a health care product, a dietary supplement, a functional food, a medical food or a nutritional supplement by adopting the existing technology. The traditional Chinese medicine composition has the effects of effectively nourishing nerve cells, improving the brain sensitivity and improving the cognitive function. The composition is particularly directed at age-related cognitive decline and neurodegenerative diseases. Repair and regeneration of nerve cells can be promoted, the transmission efficiency of neural signals is enhanced, and the overall working efficiency of the brain is improved. Daily life challenges caused by cognitive decline can be relieved, and individual life quality can be improved.
Owner:BEIJING PUCHEN TECHNOLOGY CO LTD

SiRNA for targeted inhibition of AGT gene expression and application thereof in treatment of hypertension

The invention provides a modified oligonucleotide sequence and application thereof. A series of siRNAs are designed based on an angiotensinogen (AGT) messenger ribonucleic acid (mRNA) sequence, alternate modification is carried out, and modification is carried out by utilizing a group of specific modification templates. Cellular and animal experiment results show that some alternately modified and specific template modified oligonucleotide sequences can significantly inhibit the expression of AGT genes, and can be used for developing drugs for treating hypertension and other related diseases.
Owner:HANGZHOU TIANLONG PHARM CO LTD

Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.
Owner:REMEDY PHARMACEUTICALS INC

Macitentan-containing preparation

To inhibit delayed dissolution of a macitentan-containing preparation after being kept under open conditions prone to humidity, and to suppress the formation of macitentan analogues.SOLUTION: According to one embodiment of the present invention, there is provided a macitentan-containing preparation comprising granules containing macitentan and an additive other than the granules, wherein the granules contain at least one kind of a disintegrant selected from the group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, carmellose, and calcium carmellose.SELECTED DRAWING: None
Owner:SAWAI PHARMA

Diaminocyclopentyl substituted heteroaryl derivatives, use thereof and preparation method therefor

Provided are diaminocyclopentyl substituted heteroaryl derivatives, the use thereof and a preparation method therefor. In particular, the present disclosure relates to compounds represented by formula (I)each substituent of which is defined in the description, and a preparation method therefor. The compounds can be used as PCSK9 inhibitors to prevent and / or treat PCSK9-mediated diseases and disorders.
Owner:TUOJIE BIOTECH (SHANGHAI) CO LTD

Nitrogen-containing heterocyclic compound and use thereof

A nitrogen-containing heterocyclic compound and the use thereof, and specifically disclosed are a compound as represented by formula (II), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
Owner:JIANGSU DEYUAN PHARMA